| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 17.81 | -0.26 (-1.44%) | 15.35 - 25.40 | 863.4 thousand (Below Avg) |
Market data as of 4:00PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 18.23 |
|---|---|
| Previous Close | 18.07 |
| Day's Range | 17.65 - 18.39 |
| Market Cap | 3.3B |
| Avg Volume (10 Day) | 2.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.35 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
ARIAD Announces Webcast of Its Annual Shareholders Meeting
Business Wire - Thursday 06/13/2013 7:35 AM ET
ARIAD Announces Initiation of Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
Business Wire - Tuesday 06/11/2013 7:35 AM ET
ARIAD to Present at Upcoming Investor Conferences
Business Wire - Tuesday 06/04/2013 7:30 AM ET
ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study
Business Wire - Sunday 06/02/2013 9:00 AM ET
ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
Business Wire - Sunday 06/02/2013 9:00 AM ET
ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig® (Ponatinib)
Business Wire - Saturday 06/01/2013 9:00 AM ET
ARIAD to Present at the Jefferies 2013 Global Healthcare Conference
Business Wire - Thursday 05/30/2013 7:35 AM ET
ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference
Business Wire - Thursday 05/23/2013 7:35 AM ET
| ARIA | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -72.59% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.08 | |
| LT Debt/Equity | 0.08 | |
| Earnings Yield | -- | |
| Price/Sales | 480.82 |
| Company | Last | Change |
|---|---|---|
| Theravance Inc | 35.41 | -1.75% |
| Incyte Corp | 21.06 | 0.00% |
| Medivation Inc | 47.41 | 0.00% |
| Questcor Pharmaceuticals Inc | 45.19 | -2.06% |
| Seattle Genetics Inc | 31.98 | -2.29% |
Data is delayed by at least 15 min.